The partnership will aid patients in an era of high-deductible health plans, which call on patients to make more of their own healthcare decisions.
Science 37, best-known for “site-less” clinical trials, and VisualDx, a diagnostic clincial decision support system, today announced a partnership to help patients work with their doctors to make better decisions about diagnosing and managing skin problems.
The agreement calls for the 2 companies to reach patients and clinicians in their respective networks to raise awareness about clinical trials and increase participation. According to a joint statement from the companies emailed to The American Journal of Managed Care®, “The synergies will come from combining VisualDx’s consumer reach and expert curated diagnostic database of over 100,000 skin-related images with Science 37’s patient-driven content and media production capabilities.”
Belinda Tan, MD, PhD, chief medical officer and co-founder of Science 37, who is a dermatologist, noted that the rise of high-deductible health plans increasingly puts patients in decision-making roles in managing their own healthcare. “Doctors aren’t always available to be your guide, so we all go online to learn more, and that’s why finding accurate medical information is critical,” she said. “The partnership with VisualDx aims to provide patients with more high quality educational content to help them make better healthcare decisions, including whether or not to participate in a clinical trial.”
“Despite increased availability and improvements in public information and mobile technology, the barriers to accurate diagnosis and access to clinical trials remain too high,” said Art Papier MD, CEO and co-founder of VisualDx. “Partnering with Science 37 brings incredible resources to our clinicians and patients including matching patients to clinical trials they can participate in from the comfort of their home.”
Decisions and Precision in Value-Based Cancer Care
January 7th 2025An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen